ANO1 and prostate cancer: TMEM16A has been found to be overexpressed in cancer samples from patients with breast cancer [42, 43], lung cancer [51], oral squamous cell carcinoma [97], esophageal cancer [121], GIST [122], prostate cancer [53], and gastric cancer [54] (Table 1).